BRAF and neoplasm: In preclinical models and in retrospective analyses of patients undergoing BRAF inhibitor therapy, blockade of this pathway was linked to a more favorable microenvironment function, with an increased number of activated tumor‐infiltrating lymphocytes (Frederick et al., 2013).